Latest procedure for enlarged prostate now available

More than 37 million men in the United States are affected by benign prostatic hyperplasia (BPH). BPH is an enlarged prostate gland and occurs in almost all men as they age. BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. (Not to be confused with prostate cancer.) Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

The introduction of the UroLift System as a treatment option for men with enlarged prostate has fundamentally changed how this condition is treated. Patients finally have a safe and simple alternative to procedures that involve cutting, heating or removal of prostate tissue. The UroLift System is minimally invasive and typically allows patients to discontinue taking medications and preserves sexual function.

The UroLift System is a proven treatment that can get men off BPH medications and allows them to avoid major surgery, while preserving sexual function.

Long-term clinical data from the LIFT randomized study published in Urologic Clinics of North America showed that, after four years, patients treated with the UroLift device continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift device compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

FOR MORE INFORMATION:

Learn more at www.UroLift.com.